

Position Statement; Prescribing of Brimonidine Tartrate 3mg/g Gel (Mirvaso®) is not supported

Castle Point and Rochford and Southend Clinical Commissioning Groups do not support the prescribing of Brimonidine tartrate 3mg/g Gel (Mirvaso®) as it is considered to be a cosmetic product.

Mirvaso® contains the active ingredient Brimonidine tartrate 3mg/g and is licensed for symptomatic treatment of facial erythema of rosacea in adult patients. It achieves this by direct vasoconstriction of superficial peripheral blood vessels.

Its use is considered to be cosmetic in nature and therefore Mirvaso® is **not** recommended for prescribing.

For further information please refer to the East of England Priorities Advisory Committee guidance statement January 2015. <https://www.nice.org.uk/advice/esnm43/chapter/Key-points-from-the-evidence>

Providers commissioned to provide services on behalf of Castle Point and Rochford and Southend CCGs are reminded that they are required to follow the Castle Point and Rochford and Southend CCGs formulary and prescribing guidance as detailed in their contract (Medicines Management Service Specification).

See Southend and Castle Point and Rochford CCGs websites – Medicines management for all prescribing guidance.

Approved for use in Castle Point & Rochford and Southend CCGs	Drugs and Therapeutics Committee 7 th December 2016
Title	Brimonidine tartrate 3mg/g gel (Mirvaso®)
Reference:	PrescQIPP Priorities Advisory Committee Jan 2015

Reviewed and adapted for use from Mid Essex CCG Prescribing Policy Statements